Table of Contents

Tumor Biology and Immunology

• 

  Tumor Biology and Immunology | AuthorChoice

  Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion

  Brian Koss, Bradley D. Shields, Erin M. Taylor, Aaron J. Storey, Stephanie D. Byrum, Allen J. Gies, Charity L. Washam, Samrat Roy Choudhury, Jeong Hyun Ahn, Hidetaka Uryu, Jason B. Williams, Kimberly J. Krager, Tung-Chin Chiang, Samuel G. Mackintosh, Rick D. Edmondson, Nukhet Aykin-Burns, Thomas F. Gajewski, Gang Greg Wang and Alan J. Tackett

  Cancer Res November 1 2020 80 (21) 4707-4719; DOI:10.1158/0008-5472.CAN-20-0524

  
  

  These findings demonstrate that manipulation of T-cell EZH2 in cellular therapies may yield cellular products able to withstand solid tumor metabolic–deficient environments.
• Tumor Biology and Immunology

  Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST

  Katherine E. Chaney, Melissa R. Perrino, Leah J. Kershner, Ami V. Patel, Jianqiang Wu, Kwangmin Choi, Tilat A. Rizvi, Eva Dombi, Sara Szabo, David A. Largaespada and Nancy Ratner

  Cancer Res November 1 2020 80 (21) 4720-4730; DOI:10.1158/0008-5472.CAN-19-1429

  
  

  New mouse models recapitulate the stepwise progression of NF1 tumors and will be useful to define effective treatments that halt tumor growth and tumor progression in NF1.
• Tumor Biology and Immunology

  PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors

  Surya Murty, Louai Labanieh, Tara Murty, Gayatri Gowrishankar, Tom Haywood, Israt S. Alam, Corinne Beinat, Elise Robinson, Amin Aalipour, Dorota D. Klysz, Jennifer R. Cochran, Robbie G. Majzner, Crystal L. Mackall and Sanjiv S. Gambhir

  Cancer Res November 1 2020 80 (21) 4731-4740; DOI:10.1158/0008-5472.CAN-19-3579

  
  

  This study showcases the only genetically engineered system capable of serving the dual role both as an effective PET imaging reporter and as a suicide switch for CAR T cells.
• Tumor Biology and Immunology

  YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma

  Jenny Shim, Jasmine Y. Lee, Hunter C. Jonus, Amanda Arnold, Robert W. Schnepp, Kaitlyn M. Janssen, Victor Maximov and Kelly C. Goldsmith

  Cancer Res November 1 2020 80 (21) 4741-4753; DOI:10.1158/0008-5472.CAN-20-0025

  
  

  This study identifies HRK as a novel tumor suppressor in neuroblastoma and suggests dual MEK and YAP inhibition as a potential therapeutic strategy in RAS-hyperactivated neuroblastomas.
• Tumor Biology and Immunology

  A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer

  Tamas A. Gonda, Jarwei Fang, Martha Salas, Catherine Do, Emily Hsu, Anna Zhukovskaya, Ariel Siegel, Ryota Takahashi, Zoila A. Lopez-Bujanda, Charles G. Drake, Gulam A. Manji, Timothy C. Wang, Kenneth P. Olive and Benjamin Tycko

  Cancer Res November 1 2020 80 (21) 4754-4767; DOI:10.1158/0008-5472.CAN-20-0285

  
  

  In a pancreatic cancer model, a DNA hypomethylating drug increases tumor-infiltrating effector T cells, increases a subset of M2 macrophages, and significantly prolongs survival in combination with immune checkpoint inhibitors.
• Tumor Biology and Immunology

  YAP and AP-1 Cooperate to Initiate Pancreatic Cancer Development from Ductal Cells in Mice

  Jaeoh Park, David Eisenbarth, Wonyoung Choi, Hail Kim, Chan Choi, Dahye Lee and Dae-Sik Lim

  Cancer Res November 1 2020 80 (21) 4768-4779; DOI:10.1158/0008-5472.CAN-20-0907

  
  

  A pancreatic ductal cell-specific knockout mouse model featuring constitutively active YAP allows for the study of YAP-dependent transformation of the pancreas and for screening pharmacologically active inhibitors.
• Tumor Biology and Immunology | AuthorChoice

  Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease

  Israt S. Alam, Federico Simonetta, Lukas Scheller, Aaron T. Mayer, Surya Murty, Ophir Vermesh, Tomomi W. Nobashi, Juliane K. Lohmeyer, Toshihito Hirai, Jeanette Baker, Kenneth H. Lau, Robert Negrin and Sanjiv S. Gambhir

  Cancer Res November 1 2020 80 (21) 4780-4790; DOI:10.1158/0008-5472.CAN-20-1149

  
  

  OX40-immunoPET imaging is a promising noninvasive strategy for early detection of GvHD, capable of detecting signs of GvHD pathology even prior to the development of overt clinical symptoms.
• Tumor Biology and Immunology

  Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer

  Piotr Przanowski, Song Lou, Rachisan Djiake Tihagam, Tanmoy Mondal, Caroline Conlan, Gururaj Shivange, Ilyas Saltani, Chandrajeet Singh, Kun Xing, Benjamin B. Morris, Marty W. Mayo, Luis Teixeira, Jacqueline Lehmann-Che, Jogender Tushir-Singh and Sanchita Bhatnagar

  Cancer Res November 1 2020 80 (21) 4791-4804; DOI:10.1158/0008-5472.CAN-20-1459

  
  

  TRIM37 drives aggressive TNBC biology by promoting resistance to chemotherapy and inducing a prometastatic transcriptional program; inhibition of TRIM37 increases chemotherapy efficacy and reduces metastasis risk in patients with TNBC.
• Tumor Biology and Immunology

  CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss

  Cai Bowen, Maho Shibata, Hailan Zhang, Sarah K. Bergren, Michael M. Shen and Edward P. Gelmann

  Cancer Res November 1 2020 80 (21) 4805-4814; DOI:10.1158/0008-5472.CAN-20-1742

  
  

  These findings show that prolonging the half-life of Nkx3.1 reduces proliferation, enhances DNA end-labeling, and protects from DNA damage, ultimately blocking the proneoplastic effects of Nkx3.1 allelic loss.